1. Pink Sheet

Closing Thoughts On US FDA Advisory Committee Reforms

 
• By Michael McCaughan

One speaker at the US FDA’s day-long “listening session” on advisory committee reform captured an important truth: the problem is not necessarily how committees are run, it is that there are no alternatives for public input into agency decisions.

Window into empty store
The FDA may need a larger window into its decision-making. • Source: Shutterstock

The US Food and Drug Administration’s day-long “listening session” on ideas to reform the advisory committee process bore an uncanny resemblance to the regular open public hearing in those meetings.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers